US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Kailera Therapeutics

10.79

-0.6300-5.52%

Volume:84.76K

Turnover:941.60K

Market Cap:1.40B

PE:-4.79

High:11.75

Open:11.39

Low:10.69

Close:11.42

52wk High:28.23

52wk Low:10.69

Shares:129.54M

Float Shares:44.92M

Volume Ratio:0.56

T/O Rate:0.19%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.2543

EPS(LYR):-7,819.9811

ROE:-36.90%

ROA:-22.73%

PB:1.25

PE(LYR):0.00

Loading ...

Overview Company News Filings

Earning Preview: Kailera Therapeutics this quarter’s revenue is expected to increase by 0%, and institutional views are bullish

Kailera Therapeutics Files Form 3 for Chief Corporate Affairs Officer Kathleen Tregoning

Jefferies Keeps Their Buy Rating on Kailera Therapeutics, Inc. (KLRA)

Analysts Offer Insights on Healthcare Companies: Acadia Healthcare (ACHC) and Kailera Therapeutics, Inc. (KLRA)

Race to Launch Weight-loss Pills Heats up as Smaller Players Advance

Wall Street Analysts Are Bullish on Top Healthcare Picks

Kailera Therapeutics announces positive Phase 3 data for weight loss drug

Shares of Kailera Therapeutics up 1.9% Premarket After Weight-loss Drug Meets Main Goal of Late-stage Trials in China

THOMSON REUTERS

Kailera Shares Tumble on High Nausea Rates Despite Weight-loss Drug's Success

Kailera's GLP-1 Drug Meets Main Goal of Late-stage Trials

Kailera Reports Phase 3 China Data Showing up to 10.9% Weight Loss with Oral GLP-1 Drug Kai-7535

Kailera Therapeutics - Hrs-7535 Lowers Hba1c by 1.5%-1.68% in Phase 3 Type 2 Diabetes Trial

THOMSON REUTERS

Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule Glp-1 Receptor Agonist Hrs-7535/kai-7535

THOMSON REUTERS

Kailera Therapeutics Inc: Advancing Kai-7535 in a Global Phase 2 Clinical Trial in People Living with Obesity or Overweight

THOMSON REUTERS

Kailera Therapeutics Inc: Kai-7535 Trial Initiated in April 2026, with Data Expected in 2027

THOMSON REUTERS

Kailera Therapeutics - no Liver Safety Signals Observed in Phase 3 Trials of Hrs-7535

THOMSON REUTERS

Press Release: Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer

Kailera Therapeutics - Phase 2 Ribupatide Oral Shows up to 12.1% Mean Weight Loss at 26 Weeks

THOMSON REUTERS

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Kailera Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/KLRA/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KLRA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KLRA\",,,,,undefined,":{"symbol":"KLRA","market":"US","secType":"STK","nameCN":"Kailera Therapeutics","latestPrice":10.79,"timestamp":1790863610814,"preClose":11.42,"halted":0,"volume":84756,"delay":0,"changeRate":-0.05516637478108588,"floatShares":44921899,"shares":129537300,"eps":-2.254252,"marketStatus":"Trading","change":-0.63,"latestTime":"10-01 10:06:51 EDT","open":11.39,"high":11.75,"low":10.69,"amount":941603.392968,"amplitude":0.09282,"askPrice":10.8,"askSize":100,"bidPrice":10.75,"bidSize":98,"shortable":3,"etf":0,"ttmEps":-2.254252,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1790884800000},"marketStatusCode":2,"adr":0,"listingDate":1776398400000,"exchange":"NASDAQ","adjPreClose":11.42,"preHourTrading":{"tag":"盘前","latestPrice":11.42,"preClose":11.42,"latestTime":"08:19 EDT","volume":16,"amount":182.72,"timestamp":1790857185140,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":11.42,"preClose":11.42,"latestTime":"19:30 EDT","volume":36857,"amount":420906.92,"timestamp":1790811003210,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.559601},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KLRA\",,,,,undefined,":{"symbol":"KLRA","floatShares":44921899,"roa":"-22.73%","roe":"-36.90%","lyrEps":-7819.9811,"volumeRatio":0.559601,"shares":129537300,"dividePrice":0,"high":11.75,"amplitude":0.09282,"preClose":11.42,"low":10.69,"week52Low":10.69,"pbRate":"1.25","week52High":28.2271,"institutionHeld":0,"latestPrice":10.79,"committee":-0.010101,"eps":-2.254252,"divideRate":0,"volume":84756,"delay":0,"ttmEps":-2.254252,"open":11.39,"prevYearClose":16,"prevWeekClose":11.215,"prevMonthClose":11.42,"prevQuarterClose":11.42,"fiveDayClose":11.98,"twentyDayClose":15.85,"sixtyDayClose":21.76},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KLRA\",params:#limit:5,,,undefined,":[{"date":"2026-11-04","symbol":"KLRA","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1793826000000,"name":null,"time":"Post-Mkt","dateTimestamp":1793768400000,"actualEps":null},{"market":"US","date":"2026-08-12","symbol":"KLRA","fiscalQuarterEnding":"2026/06","expectedEps":-0.74,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786507200000,"reportTimeType":"post","actualEps":-1.09}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KLRA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KLRA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":6,"updateTime":1783483200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KLRA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KLRA","date":"2026-09-30","current":-5.065982,"percent":1,"low":-21.871461,"twenty":-18.817283,"median":-12.75669,"eighty":-7.562182,"high":-4.876108,"avg":-13.331086,"sd":5.292403,"marketCap":1424783999},"quantilePoints":[{"date":"2026-04-17","current":-12.669466,"twenty":-12.511098,"median":-12.273546,"eighty":-12.035993,"marketCap":1887180368},{"date":"2026-04-24","current":-20.824025,"twenty":-20.917019,"median":-20.433783,"eighty":-14.17085,"marketCap":3101842710},{"date":"2026-05-01","current":-21.741015,"twenty":-21.413894,"median":-20.305085,"eighty":-18.829635,"marketCap":3238432850},{"date":"2026-05-08","current":-19.540824,"twenty":-21.576784,"median":-20.824025,"eighty":-19.524523,"marketCap":2910703445},{"date":"2026-05-15","current":-18.697273,"twenty":-21.521865,"median":-20.058623,"eighty":-18.676401,"marketCap":2785052251},{"date":"2026-05-22","current":-18.332024,"twenty":-21.403595,"median":-19.540824,"eighty":-18.304195,"marketCap":2730646579},{"date":"2026-05-29","current":-19.949555,"twenty":-21.097481,"median":-19.520448,"eighty":-18.332024,"marketCap":2971585983},{"date":"2026-06-05","current":-18.253756,"twenty":-20.940268,"median":-19.530636,"eighty":-18.332024,"marketCap":2718988220},{"date":"2026-06-12","current":-16.992777,"twenty":-20.824025,"median":-19.392985,"eighty":-17.13192,"marketCap":2531159115},{"date":"2026-06-18","current":-16.636224,"twenty":-20.511831,"median":-18.758148,"eighty":-17.050173,"marketCap":2478048816},{"date":"2026-06-26","current":-12.75669,"twenty":-20.227867,"median":-18.684228,"eighty":-17.050173,"marketCap":2676825461},{"date":"2026-07-02","current":-12.855483,"twenty":-20.165517,"median":-18.622605,"eighty":-16.764931,"marketCap":2697555958},{"date":"2026-07-10","current":-12.9728,"twenty":-20.033041,"median":-18.410291,"eighty":-15.433812,"marketCap":2722173424},{"date":"2026-07-17","current":-11.311837,"twenty":-19.949555,"median":-18.314631,"eighty":-13.521103,"marketCap":2373641938},{"date":"2026-07-24","current":-10.743775,"twenty":-19.944337,"median":-17.453687,"eighty":-12.859187,"marketCap":2254441579},{"date":"2026-07-31","current":-10.527665,"twenty":-19.923466,"median":-17.13192,"eighty":-12.704356,"marketCap":2209093616},{"date":"2026-08-07","current":-11.651439,"twenty":-19.849563,"median":-17.071044,"eighty":-11.79378,"marketCap":2444903022},{"date":"2026-08-14","current":-7.973035,"twenty":-19.724778,"median":-16.992777,"eighty":-11.573639,"marketCap":2329696857},{"date":"2026-08-21","current":-7.746755,"twenty":-19.603438,"median":-16.640572,"eighty":-11.334065,"marketCap":2263578582},{"date":"2026-08-28","current":-8.221499,"twenty":-19.532674,"median":-16.131833,"eighty":-11.014222,"marketCap":2402297316},{"date":"2026-09-04","current":-6.983615,"twenty":-19.497291,"median":-13.667441,"eighty":-10.594351,"marketCap":2040591460},{"date":"2026-09-11","current":-6.615356,"twenty":-19.448642,"median":-13.506901,"eighty":-10.353542,"marketCap":1932987209},{"date":"2026-09-18","current":-5.732421,"twenty":-19.325153,"median":-12.9728,"eighty":-8.138973,"marketCap":1674996293},{"date":"2026-09-25","current":-5.315357,"twenty":-18.99469,"median":-12.812261,"eighty":-7.882523,"marketCap":1553131238},{"date":"2026-09-30","current":-4.876108,"twenty":-18.817283,"median":-12.75669,"eighty":-7.562182,"marketCap":1424783999}],"updateTime":1790856800663},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KLRA\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1126637747","title":"Earning Preview: Kailera Therapeutics this quarter’s revenue is expected to increase by 0%, and institutional views are bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=1126637747","media":"Earnings Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126637747?lang=en_us&edition=fundamental","pubTime":"2026-08-05 10:27","pubTimestamp":1785896846,"startTime":"0","endTime":"0","summary":"Abstract Kailera Therapeutics will report fiscal results on August 12, 2026 Post-Mkt, with the market looking for zero revenue, a forecast adjusted EPS of -0.75, and EBIT of -120.50 million US...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Earning Preview: Kailera Therapeutics this quarter’s revenue is expected to increase by 0%, and institutional views are bullish","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650152659","title":"Kailera Therapeutics Files Form 3 for Chief Corporate Affairs Officer Kathleen Tregoning","url":"https://stock-news.laohu8.com/highlight/detail?id=2650152659","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650152659?lang=en_us&edition=fundamental","pubTime":"2026-07-09 04:16","pubTimestamp":1783541765,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics files Form 3 for Chief Corporate Affairs Officer Kathleen TregoningKailera Therapeutics named Kathleen Tregoning as chief corporate affairs officer in an initial Form 3 filing dat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260708:nNDL8l21D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRA","OZEM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649099976","title":"Jefferies Keeps Their Buy Rating on Kailera Therapeutics, Inc. (KLRA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2649099976","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649099976?lang=en_us&edition=fundamental","pubTime":"2026-07-08 21:35","pubTimestamp":1783517747,"startTime":"0","endTime":"0","summary":"In a report released today, Roger Song from Jefferies maintained a Buy rating on Kailera Therapeutics, Inc., with a price target of $48.00. Song co...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jefferies-keeps-their-buy-rating-on-kailera-therapeutics-inc-klra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jefferies-keeps-their-buy-rating-on-kailera-therapeutics-inc-klra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649346689","title":"Analysts Offer Insights on Healthcare Companies: Acadia Healthcare (ACHC) and Kailera Therapeutics, Inc. (KLRA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2649346689","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649346689?lang=en_us&edition=fundamental","pubTime":"2026-07-08 01:30","pubTimestamp":1783445416,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Acadia Healthcare (ACHC) and Kailera Therapeutics, Inc. (KLRA). A...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-acadia-healthcare-achc-and-kailera-therapeutics-inc-klra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-acadia-healthcare-achc-and-kailera-therapeutics-inc-klra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OZEM","BK4588","LABU","BK4581","BK4185","BK4585","KLRA","XLV","ACHC","XBI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649402939","title":"Race to Launch Weight-loss Pills Heats up as Smaller Players Advance","url":"https://stock-news.laohu8.com/highlight/detail?id=2649402939","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649402939?lang=en_us&edition=fundamental","pubTime":"2026-07-08 00:12","pubTimestamp":1783440755,"startTime":"0","endTime":"0","summary":"FACTBOX-Race to launch weight-loss pills heats up as smaller players advanceAdds details of Kailera Therapeutics' obesity drug in paragraphs 1,2 and 25July 7 (Reuters)-Kailera Therapeutics'KLRA.Ooral ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nL4N4391DU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1989772923.USD","LU2168564149.EUR","RXL","PFE","LU2097828474.EUR","LU2237443978.SGD","THNR","FTXH","IE0009355771.USD","LU0471298777.SGD","VKTX","LU0208291251.USD","LU1037948541.HKD","LU2360032135.SGD","LU2328871848.SGD","LU1868836757.USD","LU2211815571.USD","LU1116320737.USD","LU2028103732.USD","LU0965508806.USD","SG9999014559.SGD","LU0321505868.SGD","LU0320765646.SGD","LU2213496289.HKD","SG9999002224.SGD","LU2746668461.USD","LLY","NVOH","ELIL","BK4581","BK4559","LU1066051225.USD","LU2089984988.USD","LU1699723380.USD","LU0225284248.USD","LU0861579265.USD","LU0109394709.USD","LU1093756325.SGD","IE00B3T34201.USD","LU0787776722.HKD","SG9999001440.SGD","SGXZ81514606.USD","LU2471134952.CNY","LU2087625088.SGD","IE00B19Z3581.USD","SG9999015358.SGD","LU2468319806.SGD","LU2236285917.USD","PPH","LU0353189763.USD","LU1894683348.USD","LU1934455194.USD","LU0061475181.USD","LU0820561818.USD","LU2106854487.HKD","LU1548497426.USD","LU2357305700.SGD","IE00B4R5TH58.HKD","LU1145028129.USD","LU1061106388.HKD","LU1720051108.HKD","LU2361044949.HKD","LU0882574055.USD","LU0868494708.USD","BK4550","LU0321505439.SGD","LU0466842654.USD","LU0859254822.USD","MEDX","LU0456855351.SGD","LU0098860793.USD","BK4568","LU0158827781.USD","LU2357627491.SGD","LU0256863902.USD","IE00BLSP4239.USD","SG9999015945.SGD","NVO","IE00B1BXHZ80.USD","LU2097828714.EUR","LU2896262040.SGD","LU0114720955.EUR","LU1127390331.HKD","LU2596442595.SGD","LU0203345920.USD","LU2023251221.USD","LU1623119135.USD","LU1868836914.USD","LU0130102774.USD","LU2471134796.USD","LU1037948897.HKD","LU1883839398.USD","LU2125154778.USD","KLRA","LU0820562030.AUD","LU1814569148.SGD","LU1929549753.HKD","LU0345770308.USD","SG9999014898.SGD","LU2237443382.USD","IE00B775H168.HKD","BK4585","LLYX","IE00BKPKM429.USD","LU1023059063.AUD","BK1589","LU0058720904.USD","LU2089283258.USD","LU1969619763.USD","GB00BDT5M118.USD","LU1162221912.USD","AZNH","LU2552382058.USD","LU0130517989.USD","IE00BN8TJ469.HKD","PJP","LU1323610961.USD","SG9999014914.USD","LU1917777945.USD","LU2063271972.USD","LU2433249047.HKD","LU0320765992.SGD","LU2237443549.SGD","LU1629891620.HKD","LU0323591593.USD","LU0128525929.USD","SG9999018857.SGD","LU2361045086.USD","LU0306806265.USD","IE00B2B36J28.USD","LU1057294990.SGD","BK4533","LU0823434740.USD","LU2265009873.SGD","IYH","IE00BJT1NW94.SGD","LU0354030438.USD","IE00BN29S564.USD","LU0964807845.USD","WDNA","LU0006306889.USD","LU0070302665.USD","LU2089284900.SGD","LU1829250122.USD","BK4592","IE00B1XK9C88.USD","BK4588","SGXZ31699556.SGD","LU2111349929.HKD","OZEM","SG9999014567.USD","LU0965509101.SGD","LU2552382215.SGD","LU0965509283.SGD","LU1069347547.HKD","LU0672654240.SGD","LU1868837300.USD","LU1064131342.USD","LU1066051498.USD","IE00BJLML261.HKD","LU0820561909.HKD","IE00BK4W5L77.USD","LU0170899867.USD","IXJ","LU1232071149.USD","SG9999015952.SGD","SG9999015978.USD","IE0005OL40V9.USD","LU0265550946.USD","SGXZ51526630.SGD","LU0211331839.USD","IE00BBT3K403.USD","LU2264538146.SGD","SG9999002232.USD","IE00B19Z3B42.SGD","LU1551013425.SGD","BK1583","LU0203201768.USD","LU1894683264.USD","LU2125909593.SGD","LU2168564065.EUR","LU0256863811.USD","LU0943347566.SGD","NVOX","LU1989771016.USD","IE00BFSS7M15.SGD","LU2237438978.USD","LU0965509010.AUD","LU0823434583.USD","LU2168564495.EUR","LU0320765059.SGD","LU1989772840.SGD","LU1066051811.HKD","IE00BFSS8Q28.SGD","SG9999017495.SGD","LU0310800379.SGD","BK4007","LU1923622614.USD","LU2461242641.AUD","LU0079474960.USD","IE00BSNM7G36.USD","LU0203202063.USD","LU0477156953.USD","LU0133085943.USD","LU0942090050.USD","GPCR","IE00B7KXQ091.USD","BMED","LU0316494557.USD","LU1868837136.USD","LU2023250330.USD","LU0385154629.USD","AGNG","LU1974910355.USD","MEDI","LU2471134879.HKD","LU0106261372.USD","BK4516","LU2491049909.HKD","LU0432979614.USD","SG9999011175.SGD","IE0002141913.USD","LU0096364046.USD","LU2602419157.SGD","LU2168564222.USD","SG9999001176.USD","LU0985481810.HKD","LU0122379950.USD","SG9999014575.USD","CANC","LU0455707207.USD","LU1983299246.USD","IE0004445015.USD","LU0417517546.SGD","01801","LU1066053197.SGD","LU0265550359.USD","LU0345770993.USD","IE0002270589.USD","LU2271345857.HKD","LU0640476718.USD","IE00BKVL7J92.USD","SG9999015986.USD","LU0689472784.USD","LU2456880835.USD","LLYZ","LU1988902786.USD","IE00BJJMRZ35.SGD","LU2746668974.SGD","SG9999003800.SGD","LU2360106947.USD","LU2237443465.HKD","IE00BWXC8680.SGD","LU2488822045.USD","LLII","LU2491050071.SGD","LU2023250843.SGD","IE000M9KFDE8.USD","LU0354030511.USD","LU2417539215.USD","LU0502904849.HKD","XLV","IE0001KFT4U8.USD","LU0029864427.USD","IE00BJJMRX11.SGD","LU0882574139.USD","SG9999018865.SGD","LU0203347892.USD","KURE","IE0004445239.USD","BK4599","LU1430594728.SGD","IE00BJJMRY28.SGD","LU0109391861.USD","LU2125909247.SGD","LU1069344957.HKD","SG9999014542.SGD","LU0154236417.USD","LU0289739699.SGD","LU1934455863.HKD","BK1161","LU0094547139.USD","LU2462157665.USD","LU1934455277.USD","01672","LU2324357040.USD","SG9999015341.SGD","LU0097036916.USD","LU0266013472.USD","LU0823416689.USD","LU2125154935.USD","IE00BZ1G4Q59.USD","IE00BKDWB100.SGD","HRTS","LU0210536198.USD","LU0158827948.USD","LU1280957306.USD","LU0868494617.USD","LU2242644610.SGD","BK4532","LU1585245621.USD","LU2112291526.USD","LU1093756168.USD","LU2168563687.JPY","MRK","LU1720051017.SGD","LU0648001328.SGD","SGXZ99366536.SGD","LU2097828631.EUR","LU0889565916.HKD","LU1941712264.USD","BK4534","LU1291159041.SGD","AZN","SG9999014906.USD","SG9999001176.SGD","IE00BLSP4452.SGD","GDOC","LU0234572021.USD","LU0225771236.USD","LU2491050154.USD","LU0683600562.USD","ILDR","VHT","LU2237443895.HKD","LU0320765489.SGD","LU2108987350.USD","BK1574","LU1804176565.USD","LU2097828805.USD","LU2750360641.GBP","LU1116320901.HKD","IHE","LU0985320562.USD","LU1571399168.USD","LU2756315318.SGD","SGXZ57979304.SGD","BK1515","LU0708995401.HKD","LU1035775433.USD","LU2237443622.USD","LU2471134523.USD","FHLC","LU0708994859.HKD","LU0353189680.USD","LU2361044865.SGD","PAWZ","LU0225283273.USD","LU1868836591.USD","LU2552382132.HKD","IE00B4JS1V06.HKD","CURE","LU0786609619.USD","LU1366192091.USD","LU0306807586.USD","BK4139","LU1941712348.USD","IE00BFTCPJ56.SGD","LU1201861249.SGD","SG9999013999.USD","IE00BK4W5M84.HKD","LU0198837287.USD","LU2097828557.USD","LU2756315664.SGD","LU0238689110.USD","LU1267930730.SGD","ELIS","LU1551013342.USD","LU0980610538.SGD","LU0471298694.HKD","LU1712237335.SGD","HK0000165453.HKD","LU1267930573.SGD","LU2750360997.AUD","LU2023250504.SGD","JDOC","LU1035773651.USD","SG9999014880.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649352259","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2649352259","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649352259?lang=en_us&edition=fundamental","pubTime":"2026-07-07 22:40","pubTimestamp":1783435211,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Kailera Therapeutics, Inc. (KLRA) and Revolution Med...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-246?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-246?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KLRA","OZEM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649933246","title":"Kailera Therapeutics announces positive Phase 3 data for weight loss drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2649933246","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649933246?lang=en_us&edition=fundamental","pubTime":"2026-07-07 21:35","pubTimestamp":1783431310,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics (KLRA) announced positive topline results from two Phase 3 clinical trials conducted by its partner, Hengrui Pharma, evaluatin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kailera-therapeutics-announces-positive-phase-3-data-for-weight-loss-drug-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kailera-therapeutics-announces-positive-phase-3-data-for-weight-loss-drug-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA","OZEM","GDOC","BMED","KLRA","MEDX","HYLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649984022","title":"Shares of Kailera Therapeutics up 1.9% Premarket After Weight-loss Drug Meets Main Goal of Late-stage Trials in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2649984022","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649984022?lang=en_us&edition=fundamental","pubTime":"2026-07-07 19:31","pubTimestamp":1783423890,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nFWN4390HR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KLRA","OZEM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649162984","title":"Kailera Shares Tumble on High Nausea Rates Despite Weight-loss Drug's Success","url":"https://stock-news.laohu8.com/highlight/detail?id=2649162984","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649162984?lang=en_us&edition=fundamental","pubTime":"2026-07-07 19:21","pubTimestamp":1783423300,"startTime":"0","endTime":"0","summary":"UPDATE 3-Kailera shares tumble on high nausea rates despite weight-loss drug's successJuly 7 (Reuters)-Kailera Therapeutics'KLRA.Oshares dropped 10% on Tuesday after its oral weight-loss drug showed h","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nL4N4390VP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1267930227.SGD","LU2324357040.USD","LU0211326839.USD","LU0496365809.HKD","SG9999001176.USD","IE00B4R5TH58.HKD","LU0526926950.USD","LU0949170426.SGD","LU0889566641.SGD","BK0188","LU2237443978.SGD","LU0310800965.SGD","LU0405327494.USD","IE0034235188.USD","LU0211327993.USD","LU1146622755.USD","LU0171276677.USD","LU2237443549.SGD","LU0784384876.USD","LU1328615791.USD","LU1481600234.SGD","LU1781817850.SGD","LU1989771016.USD","LU0960981461.USD","LU1046234339.USD","LU1267930813.SGD","LU0203345920.USD","LU2097828631.EUR","LU0957799991.USD","LU2097828557.USD","SGXZ57979304.SGD","LU1273509221.SGD","LU0289739699.SGD","AZN.UK","LU0976567544.SGD","LU2097828805.USD","03165","LU0345777659.USD","LU1064130708.USD","LU0266013472.USD","LU1880407215.USD","LU0310799852.SGD","KLRA","LU0972486137.USD","LU2237443622.USD","LU2293690249.USD","LU2089284900.SGD","OZEM","600276","LU1078025761.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649984887","title":"Kailera's GLP-1 Drug Meets Main Goal of Late-stage Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2649984887","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649984887?lang=en_us&edition=fundamental","pubTime":"2026-07-07 19:06","pubTimestamp":1783422405,"startTime":"0","endTime":"0","summary":"Kailera's GLP-1 drug meets main goal of late-stage trialsJuly 7 (Reuters)-Kailera TherapeuticsKLRA.Osaid on Tuesday its GLP-1 drug for patients with diabetes and obesity met the main goal of two-late stage trials.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nL4N4390VA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRA","BK4139","OZEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649398103","title":"Kailera Reports Phase 3 China Data Showing up to 10.9% Weight Loss with Oral GLP-1 Drug Kai-7535","url":"https://stock-news.laohu8.com/highlight/detail?id=2649398103","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649398103?lang=en_us&edition=fundamental","pubTime":"2026-07-07 19:02","pubTimestamp":1783422136,"startTime":"0","endTime":"0","summary":"Kailera reports Phase 3 China data showing up to 10.9% weight loss with oral GLP-1 drug KAI-7535Kailera reported positive topline Phase 3 results in China for oral GLP-1 agonist HRS-7535, also known a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nNDL1K8vr9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OZEM","LU1504937902.USD","LU2088747998.USD","03121","BK1601","LU2088748376.SGD","BCDF","LU0886674414.USD","BK1521","BK4585","LU1560770973.SGD","IE00B64PRP62.GBP","LU0061477393.USD","LU1163227579.USD","03145","LU1316543674.SGD","SG9999010052.SGD","LU2226123227.USD","80016","IE00BN0W2W23.USD","IE00BKPKM429.USD","SG9999014005.SGD","SG9999014021.USD","00016","LU0096374516.USD","BK4588","SUHJY","LU2210150020.SGD","BK4112","NDAQ","LU2226123490.SGD","LU1163227496.USD","BK1216","SG9999002463.SGD","SG9999014039.USD","IE00B1G9TM23.USD","IE00BGHQF748.EUR","BK1559","LU2088748293.HKD","LU2210149790.SGD","IE00B3QW5Z07.USD","KLRA","LU2095319765.USD","LU2088748020.USD","SG9999009997.SGD","LU0229494975.USD","LU0315179316.USD","IE00BSPPW651.USD","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649981789","title":"Kailera Therapeutics - Hrs-7535 Lowers Hba1c by 1.5%-1.68% in Phase 3 Type 2 Diabetes Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2649981789","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649981789?lang=en_us&edition=fundamental","pubTime":"2026-07-07 19:00","pubTimestamp":1783422004,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nTUA6FTSWX:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OZEM","BK4139","KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649981749","title":"Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule Glp-1 Receptor Agonist Hrs-7535/kai-7535","url":"https://stock-news.laohu8.com/highlight/detail?id=2649981749","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649981749?lang=en_us&edition=fundamental","pubTime":"2026-07-07 19:00","pubTimestamp":1783422004,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nTUA6FTSWX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OZEM","KLRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649817599","title":"Kailera Therapeutics Inc: Advancing Kai-7535 in a Global Phase 2 Clinical Trial in People Living with Obesity or Overweight","url":"https://stock-news.laohu8.com/highlight/detail?id=2649817599","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649817599?lang=en_us&edition=fundamental","pubTime":"2026-07-07 19:00","pubTimestamp":1783422004,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nTUA6FTSWX:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OZEM","KLRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649598173","title":"Kailera Therapeutics Inc: Kai-7535 Trial Initiated in April 2026, with Data Expected in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2649598173","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649598173?lang=en_us&edition=fundamental","pubTime":"2026-07-07 19:00","pubTimestamp":1783422004,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nTUA6FTSWX:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OZEM","KLRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649498176","title":"Kailera Therapeutics - no Liver Safety Signals Observed in Phase 3 Trials of Hrs-7535","url":"https://stock-news.laohu8.com/highlight/detail?id=2649498176","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649498176?lang=en_us&edition=fundamental","pubTime":"2026-07-07 19:00","pubTimestamp":1783422004,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nTUA6FTSWX:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KLRA","BK4139","OZEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647537613","title":"Press Release: Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2647537613","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647537613?lang=en_us&edition=fundamental","pubTime":"2026-06-29 19:30","pubTimestamp":1782732600,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641812390","title":"Kailera Therapeutics - Phase 2 Ribupatide Oral Shows up to 12.1% Mean Weight Loss at 26 Weeks","url":"https://stock-news.laohu8.com/highlight/detail?id=2641812390","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641812390?lang=en_us&edition=fundamental","pubTime":"2026-06-06 07:37","pubTimestamp":1780702671,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nFWN42D0RY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KLRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641123920","title":"Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2641123920","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641123920?lang=en_us&edition=fundamental","pubTime":"2026-06-06 07:32","pubTimestamp":1780702320,"startTime":"0","endTime":"0","summary":"Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as a once-weekly injection and a once-daily oral pill for the treatment of obesity and ove","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/05/3307661/0/en/Hengrui-Pharma-and-Kailera-Therapeutics-Present-Ribupatide-Clinical-Data-at-ADA-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4123","BK4139","AUC","PK","BK4181","LU1169590202.USD","BK4218","LU1169589451.USD","BK4023","PD","KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639168796","title":"Kailera Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2639168796","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639168796?lang=en_us&edition=fundamental","pubTime":"2026-05-29 04:05","pubTimestamp":1779998700,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., May  28, 2026  (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/28/3303260/0/en/Kailera-Therapeutics-to-Present-at-the-2026-Jefferies-Global-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","KLRA","BK4581","BK4585","BK4137","HCSG","BK4139","LU0029874061.USD","XBI","XLV","LU0128526141.USD","LABU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":2,"totalSize":89,"code":"91000000","status":"200"}]}}